Yes, semaglutide is available as a pill. The oral version is sold under the brand name Rybelsus and comes as a tablet you take once daily. It is currently FDA-approved for managing blood sugar in adults with type 2 diabetes, not for weight loss on its own. However, a higher-dose oral version is under FDA review for weight management, which could expand pill-based options significantly.
What Rybelsus Is and How It Works
Rybelsus contains the same active ingredient as the injectable versions of semaglutide (Ozempic and Wegovy). It belongs to a class of drugs called GLP-1 receptor agonists, which mimic a natural gut hormone that regulates appetite and blood sugar. The pill is available in three tablet strengths: 3 mg, 7 mg, and 14 mg. Most people start at 3 mg for 30 days, then move up to 7 mg, with the option to increase to 14 mg if more blood sugar control is needed.
Getting a protein-based drug like semaglutide past stomach acid and into the bloodstream is the core engineering challenge of the pill. Rybelsus solves this with an absorption enhancer called SNAC, a small fatty acid compound built into each tablet. SNAC does two things: it temporarily increases the permeability of the stomach lining so semaglutide molecules can pass through, and it neutralizes the local pH around the tablet, protecting semaglutide from being broken down by digestive enzymes. This process is concentration-dependent, meaning the enhancer works best when it’s highly concentrated in one spot, which is why the dosing instructions are so specific.
How to Take the Pill Correctly
Rybelsus has stricter dosing rules than most oral medications, and following them matters for the drug to absorb properly. You need to take it first thing in the morning on an empty stomach with no more than 4 ounces (about half a glass) of plain water. Then you wait at least 30 minutes before eating, drinking anything else, or taking other oral medications. Food, coffee, or even a larger volume of water can interfere with how the SNAC enhancer works and reduce how much semaglutide actually reaches your bloodstream.
The tablets should stay in their original blister packaging until you’re ready to take one, because moisture exposure can degrade them. Store them at room temperature, between 68°F and 77°F.
How the Pill Compares to the Injection
Both the pill and injectable forms of semaglutide lower blood sugar and cause weight loss, but the injectable version tends to deliver slightly more weight loss at currently approved doses. In separate clinical trials, patients lost up to about 8 pounds over 26 weeks on Rybelsus compared to about 10 pounds over 30 weeks on Ozempic. However, a real-world observational study found that both groups lost similar amounts of weight, around 13 pounds, after six months of treatment. The gap may narrow in practice because injectable patients sometimes skip doses or delay increases.
The main tradeoff is convenience versus absorption reliability. The injection (given once weekly) doesn’t depend on stomach conditions, so more of the drug consistently reaches the bloodstream. The pill requires that strict morning fasting routine every single day. For people who strongly prefer avoiding needles, the daily dosing ritual is worth it. For people who find a once-weekly injection easier to stick with, the shot may be the better fit.
Side Effects of the Pill
Gastrointestinal symptoms are the most common side effects and tend to be more frequent with the oral form. In clinical trials, up to 73% of participants reported some kind of GI issue. Nausea affected up to 44% of patients, vomiting up to 36%, diarrhea up to 30%, constipation up to 24%, and abdominal pain up to 20%. These side effects are typically mild to moderate and most common during the first few weeks or after a dose increase. They tend to improve as your body adjusts, though some people find they persist.
The gradual dose escalation schedule (starting at 3 mg and stepping up monthly) is designed to minimize these effects. Eating smaller meals, avoiding high-fat foods, and staying hydrated can also help during the adjustment period.
The Pill Is Not Yet Approved for Weight Loss
Rybelsus is approved only for type 2 diabetes management. It is not approved for weight loss in people without diabetes. Some doctors prescribe it off-label for weight management, but insurance typically won’t cover it for that purpose.
That said, a higher-dose oral semaglutide tablet (50 mg, far above the current 14 mg maximum) is under FDA review specifically for long-term weight management. If approved, it would be the first GLP-1 pill authorized for obesity treatment. The clinical trial results behind this application are strong: in a phase 3 trial published in The Lancet, adults with overweight or obesity who took the 50 mg oral dose lost an average of 15.1% of their body weight over 68 weeks, compared to 2.4% with a placebo. About 85% of participants on the drug lost at least 5% of their body weight, and roughly one in three lost 20% or more.
Gastrointestinal side effects were common at this higher dose, with 80% of participants reporting some GI symptoms, though most were rated as mild to moderate. These results are comparable to what injectable semaglutide achieves at the 2.4 mg weekly dose used in Wegovy, suggesting the pill could eventually match the injection for weight loss.
Cost and Availability
Rybelsus is available by prescription at most pharmacies. Like other GLP-1 medications, it carries a high list price, though actual out-of-pocket costs vary widely depending on insurance coverage and manufacturer savings programs. Insurance plans are more likely to cover it when prescribed for type 2 diabetes than for off-label weight loss. Generic versions of oral semaglutide are not yet available.
If the 50 mg weight management version receives FDA approval, it would likely be marketed under a different brand name or indication, similar to how injectable semaglutide is sold as Ozempic for diabetes and Wegovy for weight loss. That approval could significantly change access for people seeking a needle-free alternative to Wegovy.